Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells $809,277.00 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 36,372 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total transaction of $809,277.00. Following the completion of the sale, the chief financial officer now owns 22,958 shares in the company, valued at $510,815.50. The trade was a 61.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kiniksa Pharmaceuticals Price Performance

Shares of Kiniksa Pharmaceuticals stock traded down $0.36 on Tuesday, hitting $22.61. The company had a trading volume of 366,688 shares, compared to its average volume of 405,013. The business has a 50-day simple moving average of $20.05 and a 200-day simple moving average of $22.10. The company has a market cap of $1.64 billion, a PE ratio of -161.49 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). The business had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company's quarterly revenue was up 46.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.35 earnings per share. On average, equities research analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Remove Ads

Institutional Trading of Kiniksa Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in KNSA. Quarry LP acquired a new position in Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $50,000. Lazard Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals in the 4th quarter worth approximately $61,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Kiniksa Pharmaceuticals in the 3rd quarter worth approximately $189,000. KLP Kapitalforvaltning AS acquired a new position in Kiniksa Pharmaceuticals in the 4th quarter worth approximately $158,000. Finally, Bellevue Group AG acquired a new position in Kiniksa Pharmaceuticals in the 4th quarter worth approximately $160,000. 53.95% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target on the stock. Wedbush restated an "outperform" rating and issued a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research note on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $37.17.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.